Pharmacoeconomic review report : Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Drugs--Cost effectiveness.

Drugs.

Physical Description:

1 online resource (28 pages) : illustrations

Other Title:

Pharmacoeconomic review report Lixisenatide

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017.

Summary:

Lixisenatide (Adlyxine) is a glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes mellitus in patients uncontrolled on basal insulin with or without oral glucose-lowering agents. The starting dose is 10 mcg once daily for 14 days, then increased to 20 mcg once daily. It is supplied as a solution in a pre-filled injector pen for subcutaneous administration in strengths of 0.05 mg/mL and 0.1 mg/mL, delivering 14 doses of 10 mcg per dose or 20 mcg per dose. The submitted price of lixisenatide is $56.98 per injector pen (regardless of strength) or $1,486 annually.

Contents:

Abbreviations

Executive Summary

Background

Summary of Identified Limitations and Key Results

Conclusions

Information on the Pharmacoeconomic Submission

Summary of the Manufacturer's Pharmacoeconomic Submission

Manufacturer's Base Case

Summary of Manufacturer's Sensitivity Analyses

Limitations of Manufacturer's Submission

CADTH Common Drug Review Re-Analyses

Issues for Consideration

Patient Input

Appendix 1. Cost Comparison

Appendix 2. Summary of Key Outcomes

Appendix 3. Additional Information

Appendix 4. Summary of Other CADTH Health Technology Assessment Reviews

Appendix 5. Reviewer Worksheets

References.

Notes:

Description based on publisher supplied metadata and other sources.

Includes bibliographical references.